Ductal adenocarcinoma is a rare subtype of prostate carcinoma, accounting for 1-5% of all prostate cancers. It originates from the periurethral prostatic ducts (large ducts surrounding the main prostatic duct) and shows papillary or cribriform growth pattern. Pure ductal adenocarcinoma is rare; the majority of cases present in mixed form (ductal + acinar). Clinically, it presents with hematuria, obstructive symptoms, and sometimes a visible urethral mass — this presentation differs from acinar adenocarcinoma. PSA level may be lower than expected relative to tumor burden because the PSA production capacity of the ductal component is less than that of the acinar type. On mpMRI, a periurethral/centrally located mass with heterogeneous T2 signal, prominent enhancement, and cystic-papillary components is characteristic. In the PI-RADS v2.1 context, ductal adenocarcinoma should be considered in the differential diagnosis of centrally located lesions. Prognosis is worse than pure acinar adenocarcinoma; the risk of extraprostatic extension is high even in early stages.
Age Range
55-80
Peak Age
70
Gender
Male predominant
Prevalence
Rare
Ductal adenocarcinoma originates from the epithelium of large periurethral ducts that open into the prostatic urethra. These ducts are concentrated in the central region of the prostate and around the urethra. Tumor cells show papillary (finger-like villous projections) or cribriform (sieve-like pattern) growth — this growth pattern forms the basis of the characteristic cystic-papillary appearance on MRI. Papillary projections contain a fibrovascular core (vessels in the supporting tissue) that enhances intensely with contrast; spaces between projections appear hyperintense on T2 as the cystic component. The low PSA level in ductal adenocarcinoma results from decreased PSA (kallikrein 3) gene expression compared to the acinar type — immunohistochemical studies may show weak positive or negative PSA staining in the ductal component. The tumor can grow toward the urethral lumen forming a polypoid/papillary intraluminal mass — this explains the cause of hematuria and obstructive symptoms. Ductal adenocarcinoma tends to show stromal invasion and seminal vesicle involvement even at early stages; this aggressive biological behavior explains the worse prognosis.
Mass containing cystic spaces and prominently enhancing papillary/solid component around the prostatic urethra — this 'cystic-papillary enhancement' pattern is the most diagnostic MR finding of ductal adenocarcinoma. The combination of fibrovascular core enhancement of papillary projections + fluid-filled non-enhancing cystic spaces between projections is the signature finding distinguishing this tumor subtype from acinar adenocarcinoma.
Heterogeneous signal mass around the prostatic urethra (periurethral/centrally located) on T2-weighted images. A cystic-papillary component is characteristic: papillary projections show intermediate-to-low T2 signal, fluid-filled spaces between projections show high T2 signal. This mixed signal pattern differs from the homogeneous T2 hypointensity of pure acinar adenocarcinoma. The mass may narrow the urethra or show polypoid extension into the urethral lumen.
Report Sentence
A periurethrally located mass with cystic-papillary component showing heterogeneous T2 signal is observed around the prostatic urethra; ductal adenocarcinoma should be the leading consideration.
Early and prominent enhancement of the papillary component on dynamic contrast-enhanced MRI. Cystic spaces do not enhance; papillary projections and solid components show intense enhancement. This enhancement pattern can be described as 'septated cyst' or 'enhancing papillary component + non-enhancing cystic component'. DCE positivity is associated with high suspicion in the PI-RADS v2.1 context.
Report Sentence
Early and prominent enhancement of the papillary/solid component is observed in the periurethral mass, with cystic spaces not enhancing — consistent with the enhancement pattern of ductal adenocarcinoma.
Diffusion restriction in the solid/papillary component on DWI (hyperintense signal at high b values, hypointense signal on ADC map). The cystic component does not show diffusion restriction (free water). ADC values are low in the solid component (typically <900 x 10⁻⁶ mm²/s). This finding confirms the malignant nature of the tumor and upgrades the score in PI-RADS v2.1.
Report Sentence
Diffusion restriction and low ADC values are observed in the solid/papillary component of the periurethral mass on DWI, consistent with malignancy; the cystic component does not show diffusion restriction.
Enhancing mass around the prostatic urethra on contrast-enhanced CT. The papillary/solid component enhances while cystic areas remain low density. CT does not provide as detailed characterization as mpMRI but in large tumors, periurethral mass, seminal vesicle involvement, and pelvic lymphadenopathy may be seen. Chest and abdominal CT is valuable for staging purposes.
Report Sentence
An enhancing mass around the prostatic urethra is observed on CT with cystic areas remaining low density — may be consistent with ductal adenocarcinoma, further characterization with mpMRI is recommended.
Polypoid/papillary intraluminal mass extension in the prostatic urethral lumen on T2-weighted images. This finding is highly characteristic of ductal adenocarcinoma and is not typically seen in acinar adenocarcinoma. The intraluminal component shows intermediate-to-low T2 signal and is easily distinguished from the high-signal fluid of the urethral lumen.
Report Sentence
Polypoid/papillary intraluminal mass extension is observed in the prostatic urethral lumen, a finding highly characteristic of ductal adenocarcinoma.
Criteria
Entire tumor in ductal pattern (papillary/cribriform). Rare (0.2-0.4%). PSA weak/negative, AMACR positive, CK7 may be positive on immunohistochemistry.
Distinct Features
More aggressive course, early extraprostatic extension. Prominent cystic-papillary component on MRI. Typical presentation with hematuria. Graded as Gleason 4+4=8 (cribriform/papillary pattern = Gleason grade 4).
Criteria
Ductal + acinar components together. The vast majority of all ductal adenocarcinomas (80%+). Classified as mixed if any proportion of ductal component is present.
Distinct Features
MRI may show both periurethral cystic-papillary component and typical acinar adenocarcinoma findings in PZ/TZ. Prognosis depends on the proportion of ductal component — more ductal component means worse prognosis.
Criteria
Papillary growth pattern dominant. Tumor epithelium lining around fibrovascular core. May be seen as urethral polypoid mass on cystoscopy.
Distinct Features
Prominent papillary enhancement pattern on MRI. Intraluminal mass appearance on cystoscopy. Hematuria is the most common symptom.
Distinguishing Feature
TZ acinar adenocarcinoma shows homogeneous T2 hypointensity ('erased charcoal sign') and does not contain cystic-papillary component. Ductal adenocarcinoma is a periurethrally located mass with cystic-papillary component and prominent enhancement. Acinar type produces PSA while ductal type does not or produces little.
Distinguishing Feature
Prostatic cyst is a thin-walled, non-enhancing, T2 hyperintense cystic lesion. Ductal adenocarcinoma contains papillary solid component and this component shows prominent enhancement. No papillary projection or solid component within the cyst.
Distinguishing Feature
Utricle cyst is a midline posterior thin-walled cystic lesion opening to the verumontanum. It does not show enhancement. Ductal adenocarcinoma is periurethrally located and contains solid enhancing papillary component. Utricle cyst is usually incidentally detected in young patients.
Urgency
urgentManagement
surgicalBiopsy
NeededFollow-up
specialist-referralWhen ductal adenocarcinoma is detected, urology and urological oncology consultation is urgently required. Diagnosis can be made by TRUS-guided biopsy, but cystoscopic biopsy provides higher diagnostic accuracy for periurethral lesions. The presence of ductal pattern on biopsy is graded as Gleason grade 4 — pure ductal tumors are scored as Gleason 4+4=8. Staging is performed with mpMRI + pelvic CT/PET-PSMA. Treatment is radical prostatectomy or radiotherapy; the presence of ductal component supports a more aggressive treatment approach. Five-year survival in pure ductal adenocarcinoma is lower than acinar adenocarcinoma (50-65% vs 80%+). Wide surgical margins and careful staging are important due to the risk of early extraprostatic extension and seminal vesicle involvement.
Ductal adenocarcinoma has a more aggressive course than the acinar variant and tends to be at a more advanced stage at diagnosis. It may be detected by cystoscopy due to hematuria. PSA may be deceptively low. Treatment is radical prostatectomy + adjuvant therapy. Recurrence and metastasis rates are higher than the acinar type.